title: Cancer treatment-related cardiac toxicity: prevention, assessment and management.
abstract: Cancer therapies, especially anthracyclines and monoclonal antibodies, have been linked with increased rates of cardiotoxicity. The development of some cardiac side effects happens over several months, and changes in ejection fraction can be detected long before permanent damage or disability occurs. Advanced heart failure could be averted with better and earlier detection. Methodologies for early detection of cardiac changes include stress echocardiograms, cardiac velocity measurements, radionuclide imaging, cardiac MRI and several potential biomarkers. Many agents have been described for prophylaxis of cardiac events precipitated by cancer therapy. Prophylactic use of beta-blockers and ACE inhibitors may be considered for use with trastuzumab in breast cancer as tolerated. Recovery of cardiac function is possible early after the injury from a cancer therapy. Late complications for coronary artery disease, hypertension and arrhythmia are underappreciated. Treatments for severe cancer therapy-related cardiac complications follow the existing paradigms for congestive heart failure and coronary artery disease, although outcomes for cancer patients differ from outcomes for non-cancer patients.
authors.affiliation: UVA Division of Hematology/Oncology, University of Virginia, UVA Box 800716, Charlottesville, VA, 22908, USA.
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Fanous
authors.affiliation: UVA Division of Hematology/Oncology, University of Virginia, UVA Box 800716, Charlottesville, VA, 22908, USA. Pmd5b@hscmail.mcc.virginia.edu.
authors.forename: Patrick
authors.identifier: http://orcid.org/0000-0003-0622-725X
authors.initials: P
authors.lastname: Dillon
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D066126:Cardiotoxicity / Q000175:diagnosis* / Q000517:prevention & control* / Q000628:therapy*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents
keywords: Anthracycline; Cardioprotection; Cardiotoxicity; Recovery; Risk factors; Trastuzumab